Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study

Table 1 Clinical characteristics of study population (n = 336)

Age, years	61.8 ± 12.0
Male, n (%)	57 (17.0)
BMI, kg/m²	22.7 ± 3.7
Smoking status, n (%)	28 (8.3)
Diabetes mellitus, n (%)	29 (8.6)
Cerebral or cardiovascular disease, n (%)	6 (1.8)
RA-related parameters
Duration, years	10.6 ± 9.6
RF, IU/mL	38.5 (0–2833.6)
Anti-CCP antibody, U/mL	50.45 (0.6–3260)
CRP, mg/dL	0.1 (0.1–9.6)
DAS28-ESR	2.4 (0.78–7.20)
HAQ score	0.25 (0–2.50)
Laboratory data
Serum Cre, mg/dL	0.69 ± 0.20
eGFR, ml/min/1.73m²	74.6 ± 18.0
Blood pressure
SBP (Branchial), mmHg	122.9 ± 17.4
DBP (Branchial), mmHg	70.5 ± 11.8
Hypertension, n (%)	110 (32.7)
Urinalysis
Cre, mg/dL	93.9 ± 63.9
Na, mEq/L	102.8 ± 51.7
K, mEq/L	49.9 ± 29.9
Na/K ratio	2.60 ± 1.68
Estimated daily salt intake, g	7.80 ± 2.20
Current RA therapeutics
MTX use, n (%)	246 (73.2)
Other cs DMARDs use, n (%)	116 (34.5)
Biological agent use, n (%)	174 (51.8)
PSL use, n (%)	70 (20.8)

Continuous variables are presented as mean (± standard deviation) and categorical variables are presented as numbers (%). Data on RA-related parameters are expressed as median (range)
Abbreviations: BMI body mass index, RF rheumatoid factor, anti-CCP antibody anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, DAS28-ESR 28-joint disease activity score using erythrocyte sedimentation, HAQ health assessment questionnaire, Cre creatinine, eGFR estimated glomerular filtration, SBP systolic blood pressure, DBP diastolic blood pressure, Na sodium, K potassium, MTX methotrexate, csDMARD conventional synthetic disease modifying anti-rheumatic drugs, tsDMARD targeted synthetic DMARD, PSL prednisolone

ISSN: 1478-6362